12.04
-1.31%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zhejiang Garden Biopharmaceutical Co
Its shares trade on Shenzhen under the ticker 300401.SZ. It has been listed since 9 October 2014. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.24bn and net income of CN¥304.9m. At that date it held total assets of CN¥5.78bn and shareholders' equity of CN¥3.49bn.
Zhejiang Garden Biopharmaceutical Co., Ltd. engages in the operation of vitamin D3, and pharmaceutical manufacturing businesses. The company is headquartered in Jinhua, Zhejiang. The company went IPO on 2014-10-09. The firm's vitamin products mainly include lanolin cholesterol, food and pharmaceutical grade vitamin D3, 25-hydroxyvitamin D3 and others. The firm also focuses on the research and development, production and sales of high-tech barrier preparations in the fields of cardiovascular, nervous system and other chronic diseases. The other products of the Company include Levofloxacin Tablets, Doxofylline Injection, Lipoic Acid Injection, Escitalopram Oxalate Tablets and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 Oct 2014
- Employees
- 849
- Website
- hybiotech.com ↗
Leadership
Pay as last reported
- Mr. Xujun ShaoExecutive Chairman of the Board, since 2021CN¥786,800
- Mr. Huanzheng MaVice Chairman of the Board, General Manager, since 2017CN¥739,400
- Mr. Zhonglan WeiVice Chairman of the Board, since 2024
- Mr. Chunhua WuChief Financial OfficerCN¥573,200
- Mr. Quanheng YuDeputy General Manager, Secretary of the Board, Director, since 2008CN¥700,000
- Mr. Jiangang LiuExecutive Deputy General Manager, Director, since 2008CN¥733,400
- Mr. Xiaoping LiuDeputy General ManagerCN¥350,100
- Mr. Guoping QianDeputy General Manager, since 2013CN¥707,600
- Mr. Fusheng FangDirector
- Mr. Qinxiang ShaoDirector, since 2017
- Mr. Guowei LiIndependent Director
- Mr. Jianmiao YanIndependent DirectorCN¥91,700
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Operates vitamin D3 and pharmaceutical manufacturing businesses
- Headquartered in Jinhua, Zhejiang with 849 employees
- Offers high-tech barrier preparations for cardiovascular and nervous system diseases
Weaknesses
- No specific weaknesses mentioned in the provided information
- No details on financial performance or market position provided
- No information on competitive advantages or unique technologies
Opportunities
- Expansion in vitamin D3 product lines including lanolin cholesterol and 25-hydroxyvitamin D3
- Growth potential in high-tech barrier preparations for chronic diseases
- Potential for increased sales of pharmaceutical products like Levofloxacin Tablets
Threats
- No specific threats mentioned in the provided information
- No details on market competition or regulatory challenges
- No information on potential risks to business operations
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.